Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 5 | 2022 | 1270 | 0.880 |
Why?
|
| Interleukin-7 | 3 | 2023 | 142 | 0.670 |
Why?
|
| T-Lymphocytes | 6 | 2023 | 10180 | 0.510 |
Why?
|
| Cytokines | 4 | 2023 | 7322 | 0.480 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2023 | 2540 | 0.400 |
Why?
|
| Neuroblastoma | 1 | 2017 | 1226 | 0.340 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 570 | 0.280 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8642 | 0.270 |
Why?
|
| Glioblastoma | 1 | 2017 | 3481 | 0.210 |
Why?
|
| Chylothorax | 1 | 2022 | 84 | 0.200 |
Why?
|
| Lymphatic Abnormalities | 1 | 2022 | 133 | 0.190 |
Why?
|
| Biliary Tract | 1 | 2021 | 134 | 0.190 |
Why?
|
| Hydrodynamics | 1 | 2021 | 158 | 0.180 |
Why?
|
| Pleural Effusion | 1 | 2022 | 338 | 0.170 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2018 | 305 | 0.140 |
Why?
|
| Chimera | 1 | 2018 | 485 | 0.140 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 261 | 0.140 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 635 | 0.140 |
Why?
|
| Adoptive Transfer | 1 | 2018 | 844 | 0.130 |
Why?
|
| Neoplasms | 3 | 2022 | 21683 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 513 | 0.120 |
Why?
|
| Lymphoma | 1 | 2023 | 1877 | 0.120 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 588 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2018 | 693 | 0.120 |
Why?
|
| Salmonella enteritidis | 1 | 2013 | 17 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 820 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 3557 | 0.110 |
Why?
|
| Aneurysm, Infected | 1 | 2013 | 85 | 0.110 |
Why?
|
| Salmonella Infections | 1 | 2013 | 173 | 0.100 |
Why?
|
| Silver Nitrate | 1 | 2010 | 12 | 0.100 |
Why?
|
| Alkenes | 1 | 2010 | 57 | 0.100 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3586 | 0.090 |
Why?
|
| Aneurysm, False | 1 | 2013 | 276 | 0.090 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2010 | 276 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1988 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2022 | 4445 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 1838 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2018 | 1580 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 3772 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 1041 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2018 | 1905 | 0.070 |
Why?
|
| Liver | 2 | 2021 | 7474 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2018 | 2987 | 0.070 |
Why?
|
| Animals | 9 | 2023 | 168757 | 0.070 |
Why?
|
| Mice | 7 | 2023 | 81183 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2018 | 23403 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 16689 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2017 | 1369 | 0.060 |
Why?
|
| Thoracic Duct | 1 | 2022 | 63 | 0.050 |
Why?
|
| Lymphography | 1 | 2022 | 201 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10481 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 3523 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8428 | 0.050 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 87 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 393 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2017 | 184 | 0.040 |
Why?
|
| Humans | 10 | 2023 | 744343 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2021 | 1224 | 0.030 |
Why?
|
| Virion | 1 | 2018 | 433 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 1878 | 0.030 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 393 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2020 | 1318 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2017 | 810 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1880 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2013 | 168 | 0.030 |
Why?
|
| Urine | 1 | 2013 | 370 | 0.020 |
Why?
|
| Swine | 1 | 2021 | 5917 | 0.020 |
Why?
|
| Isomerism | 1 | 2010 | 201 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2020 | 4204 | 0.020 |
Why?
|
| Blood | 1 | 2013 | 598 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 1978 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2017 | 1904 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 537 | 0.020 |
Why?
|
| Pelvis | 1 | 2013 | 730 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1889 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4386 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 5974 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 5524 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 3912 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2010 | 1172 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 7799 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2010 | 1809 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2010 | 1889 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5442 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2017 | 11483 | 0.010 |
Why?
|
| Lipids | 1 | 2010 | 3305 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 18029 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7181 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 163280 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 57776 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 56430 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20129 | 0.010 |
Why?
|
| Child | 1 | 2017 | 77709 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 85781 | 0.010 |
Why?
|
| Male | 2 | 2017 | 350118 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2013 | 63114 | 0.000 |
Why?
|
| Middle Aged | 1 | 2017 | 213383 | 0.000 |
Why?
|
| Adult | 1 | 2017 | 214055 | 0.000 |
Why?
|
| Female | 1 | 2017 | 380194 | 0.000 |
Why?
|
Concepts
(100)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_